Cargando…
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
BACKGROUND: The adaptive immune response following COVID-19 vaccination is essential for humoral immunogenicity and clinical protection against symptomatic infections. We present the results of circulating lymphocyte profiling and their correlation with antibody response in cancer patients tested se...
Autores principales: | Nelli, Fabrizio, Fabbri, Agnese, Panichi, Valentina, Giannarelli, Diana, Topini, Giuseppe, Giron Berrios, Julio R., Virtuoso, Antonella, Marrucci, Eleonora, Mazzotta, Marco, Schirripa, Marta, Signorelli, Carlo, Chilelli, Mario G., Primi, Francesca, Silvestri, Maria A., Ruggeri, Enzo M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008127/ https://www.ncbi.nlm.nih.gov/pubmed/35461110 http://dx.doi.org/10.1016/j.intimp.2022.108774 |
Ejemplares similares
-
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study
por: Nelli, Fabrizio, et al.
Publicado: (2023) -
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients
por: Ruggeri, Enzo Maria, et al.
Publicado: (2022) -
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
por: Nelli, F., et al.
Publicado: (2022) -
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study
por: Nelli, F., et al.
Publicado: (2022) -
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
por: Nelli, F., et al.
Publicado: (2022)